Kyntra Bio Q1 net loss narrows to $15.1 million; revenue rises to $3.7 million

Kyntra Bio, Inc.

Kyntra Bio, Inc.

KYNB

0.00
  • Kyntra Bio posted Q1 2026 revenue of USD 3.74 million, up 36.5% year over year, while net loss from continuing operations narrowed to USD 15.1 million.
  • Loss per share from continuing operations improved to USD 3.74, from USD 4.15 a year earlier.
  • Cash, cash equivalents, investments, and accounts receivable totaled USD 100.3 million at March 31, supporting cash runway into 2028.
  • Phase 2 FG-3246 monotherapy trial in metastatic castration-resistant prostate cancer remained on track for interim analysis in 4Q 2026.
  • Protocol for pivotal Phase 3 roxadustat trial in lower-risk MDS anemia with high transfusion burden is being finalized following FDA feedback, with trial initiation targeted for second half of 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605111605PRIMZONEFULLFEED9717746) on May 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.